Positive EBITDA Highlights Operational Strength and Team Execution

CINCINNATI -- (Business Wire)

HealthWarehouse.com, Inc. (OTCQB:HEWA) announced today that its net sales for the third quarter ended September 30, 2026, totaled $6.51 million, a 23% decrease from the quarter ended September 30, 2025. In the first half of 2025, the U.S. Food and Drug Administration ended a nationwide program that allowed pharmacies, including HealthWarehouse.com, to offer compounded GLP-1 prescription medications during a shortfall in supply of proprietary brand-name versions.

The Company reported a net loss of $240,000 and Adjusted EBITDA of $123,000 for the third quarter this year, versus a net loss of $72,000 and Adjusted EBITDA $384,000, respectively, for the third quarter last year.

HealthWarehouse.com, a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (NABP). HealthWarehouse.com provides a platform focused on increasing access to and reducing costs of healthcare products for consumers and business partners nationwide.

Joseph Peters, President and CEO, commented, “Despite the continued challenges associated with the reduction in compounded GLP-1 sales, HealthWarehouse delivered positive Adjusted EBITDA for the period, reflecting our continued focus on operational efficiency, financial discipline, and building a sustainable business. These results are a testament to the extraordinary team at HealthWarehouse. Their dedication, hard work, and commitment to serving our customers and partners make achievements like this possible. We believe that same commitment to excellence has earned HealthWarehouse recognition as a 2026 Top Workplace by The Cincinnati Enquirer. I couldn't be prouder of this team and what we continue to accomplish together.”

HealthWarehouse.com continues to invest in proprietary technology to remain at the forefront of new developments and offerings in the world of healthcare, focusing on customer experience, operational efficiency, and scalability. Through its strategic partnership with healthwords.ai, one of the world’s leading healthcare focused artificial intelligence companies, the Company has begun to integrate artificial intelligence tools into its operating software to improve efficiency and scalability.

““We are excited to extend our strategic partnership with healthwords.ai into 2027. Our collaboration has provided an opportunity to leverage innovative artificial intelligence technology to improve operational efficiency and strengthen our technology platform. As we look ahead, HealthWarehouse and healthwords.ai are actively exploring additional opportunities to expand our collaboration, including initiatives designed to drive revenue growth, enhance our service offerings, and identify further efficiencies across our operations. We believe this partnership has significant potential, and we look forward to building on the progress we have made together.”

The Company also announced that it has appointed Colonial Stock Transfer Company, Inc. as its new transfer agent. Colonial Stock Transfer is located at 7840 S 700 E, Sandy, UT 84070 and can be reached at (801)355-5740.

Overview of Results for Three and Nine Months Ended September 30, 2026

Net Sales: Total net sales for the three and nine months ended September 30, 2026, were $6.4 million and $19.0 million, respectively, decreasing by $1.9 million (22.8%) and $20.2 million (51.5%), respectively, versus the same periods in 2025.

Prescription sales were $5.4 million and $15.8 million for the three and nine months ended September 30, 2026, respectively, a decrease of $2.2 million (29.0%) and $21.3 million (57.3%), respectively, compared with the same periods in 2025. The decrease in prescription sales was due to the expected reduction in compounded GLP-1 product sales this year, stemming from the FDA’s determinations in the first half of 2025 that the shortages of branded semaglutide and branded tirzepetide injection products had been resolved. As a result, we could no longer provide those compounded GLP-1 products beginning in the first quarter of 2026.

Sales of over-the-counter products were $934,000 and $2.9 million for the three and nine months ended September 30, 2026, respectively, increases of $291,000 (42.4%) and $1.1 million (58.7%), respectively, over the same periods in 2025, resulting primarily from an increase in advertising.

Gross Profit: Gross profit for the three and nine months ended September 30, 2026, was $3.6 million and $10.2 million, respectively, representing decreases of $15,000 and $3.1 million, respectively, compared with the same periods in 2025. The decreases were the result of lower sales, offset in part by higher margins on our direct-to-consumer and partner services prescription businesses. Gross margin percentages were 55.1% and 53.9% for the three and nine months ended September 30, 2026, respectively, which were 12.4 and 19.9 percentage points higher versus prior-year periods. The improvements were primarily due to higher margins on our direct-to-consumer and partner services prescription businesses.

Operating Expenses: Selling, general and administrative expenses were $3.8 million and $11.1 million for the three and nine months ended September 30, 2026, respectively, which were an increase of $107,000 (2.9%) and a decrease of $1.7 million (13.2%), respectively, compared with the same periods in 2025. For the three months period, expenses increased for advertising, health insurance, and shipping and shipping supplies. For the nine months period, expenses decreased for shipping and shipping supplies, salaries primarily related to direct pharmacy labor, and legal expenses.

Net Income and Adjusted EBITDA: The Company reported net losses of $240,000 and $1.0 million for the three and nine months ended September 30, 2025, respectively, compared to a net loss of $72,000 and net income of $334,000 for the same periods in 2025.

Earnings before interest, taxes, depreciation and amortization (“EBITDA”), as adjusted for stock-based compensation and certain non-recurring charges (“Adjusted EBITDA”), were $123,000 for the three months and $11,000 for the nine months ended September 30, 2026. That compares with Adjusted EBITDA of $384,000 and $1.6 million for the three and nine months ended September 30, 2025, respectively. EBITDA and Adjusted EBITDA are non-GAAP financial measures. Definitions of these non-GAAP terms and a reconciliation to GAAP measures are provided below.

Use of Non-GAAP Financial Measures

HealthWarehouse.com, Inc. (the "Company") prepares its consolidated financial statements in accordance with the United States’ generally accepted accounting principles ("GAAP"). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding EBITDA and Adjusted EBITDA, which are commonly used. In addition to adjusting net income or net loss to exclude interest, taxes, depreciation and amortization, including amortization of right of use lease asset, (“EBITDA”), Adjusted EBITDA also excludes stock-based compensation, and certain nonrecurring charges. EBITDA and Adjusted EBITDA are not measures of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company`s performance. Accordingly, management believes that disclosure of this metric offers lenders and other shareholders an additional view of the Company`s operations that, when coupled with GAAP results, provides a more complete understanding of the Company’s financial results.

Adjusted EBITDA should not be considered as an alternative to net income, net loss, or to net cash provided by or used in operating activities, as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the Company`s performance.

Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP)

About HealthWarehouse.com

HealthWarehouse.com, Inc. (OTCQB: HEWA), a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (“NABP”). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers and business partners nationwide. Based in Florence, Kentucky, the Company operates America's Leading Online Pharmacy and is a pioneer in affordable healthcare. As one of the first Approved Digital Pharmacies by the National Association of Boards of Pharmacy, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans. Learn more at www.HealthWarehouse.com.

Forward-Looking Statements

This announcement and the information incorporated by reference herein contain “forward-looking statements” as defined in federal securities laws, including but not limited to Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which statements are based on our current expectations, estimates, forecasts and projections. Statements that are not historical facts, including statements about the beliefs, expectations and future plans and strategies of the Company, are forward-looking statements. Actual results may differ materially from those expressed in forward-looking statements or in management's expectations. Important factors which could cause or contribute to actual results being materially and adversely different from those described or implied by forward looking statements include, among others, risks related to competition, management of growth, access to sufficient capital to fund our business and our growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, cyber-attacks, access to sufficient inventory, government regulation and taxation and fraud. More information about factors that potentially could affect HealthWarehouse.com's financial results is included in HealthWarehouse.com's audited Annual Reports and Quarterly Reports available at otcmarkets.com and its prior filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261113419638/en/

Contacts:

Dan Seliga, Chief Financial Officer, (800) 748-7001

Source: HealthWarehouse.com, Inc.